These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1039 related items for PubMed ID: 18559698

  • 1. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial.
    Thiele H, Schindler K, Friedenberger J, Eitel I, Fürnau G, Grebe E, Erbs S, Linke A, Möbius-Winkler S, Kivelitz D, Schuler G.
    Circulation; 2008 Jul 01; 118(1):49-57. PubMed ID: 18559698
    [Abstract] [Full Text] [Related]

  • 2. Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial.
    Gu YL, Kampinga MA, Wieringa WG, Fokkema ML, Nijsten MW, Hillege HL, van den Heuvel AF, Tan ES, Pundziute G, van der Werf R, Hoseyni Guyomi S, van der Horst IC, Zijlstra F, de Smet BJ.
    Circulation; 2010 Dec 21; 122(25):2709-17. PubMed ID: 21098442
    [Abstract] [Full Text] [Related]

  • 3. Aborted myocardial infarction in intracoronary compared with standard intravenous abciximab administration in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction.
    Eitel I, Desch S, Schindler K, Fuernau G, Schuler G, Thiele H.
    Int J Cardiol; 2011 Nov 17; 153(1):21-5. PubMed ID: 20817283
    [Abstract] [Full Text] [Related]

  • 4. Intracoronary compared to intravenous Abciximab and high-dose bolus compared to standard dose in patients with ST-segment elevation myocardial infarction undergoing transradial primary percutaneous coronary intervention: a two-by-two factorial placebo-controlled randomized study.
    Bertrand OF, Rodés-Cabau J, Larose E, Rinfret S, Gaudreault V, Proulx G, Barbeau G, Déry JP, Gleeton O, Manh-Nguyen C, Noël B, Roy L, Costerousse O, De Larochellière R, EArly Discharge after Transradial Stenting of CoronarY Arteries in Acute Myocardial Infarction (EASY-MI) Study Investigators.
    Am J Cardiol; 2010 Jun 01; 105(11):1520-7. PubMed ID: 20494655
    [Abstract] [Full Text] [Related]

  • 5. Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention: design and rationale of the Abciximab Intracoronary versus intravenously Drug Application in ST-Elevation Myocardial Infarction (AIDA STEMI) trial.
    Thiele H, Wöhrle J, Neuhaus P, Brosteanu O, Sick P, Prondzinsky R, Birkemeyer R, Wiemer M, Kerber S, Schuehlen H, Kleinertz K, Axthelm C, Zimmermann R, Rittger H, Braun-Dullaeus RC, Lauer B, Burckhardt W, Ferrari M, Bergmann MW, Hambrecht R, Schuler G, Abciximab Intracoronary versus intravenously Drug Application in ST-Elevation Myocardial Infarction (AIDA STEMI) Investigators.
    Am Heart J; 2010 Apr 01; 159(4):547-54. PubMed ID: 20362711
    [Abstract] [Full Text] [Related]

  • 6. Intracoronary versus intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: 6-month effects on infarct size and left ventricular function. The randomised Leipzig Immediate PercutaneouS Coronary Intervention Abciximab i.v. versus i.c. in ST-Elevation Myocardial Infarction Trial (LIPSIAbciximab-STEMI).
    Eitel I, Friedenberger J, Fuernau G, Dumjahn A, Desch S, Schuler G, Thiele H.
    Clin Res Cardiol; 2011 May 01; 100(5):425-32. PubMed ID: 21125288
    [Abstract] [Full Text] [Related]

  • 7. Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: cardiac magnetic resonance substudy of the AIDA STEMI trial.
    Eitel I, Wöhrle J, Suenkel H, Meissner J, Kerber S, Lauer B, Pauschinger M, Birkemeyer R, Axthelm C, Zimmermann R, Neuhaus P, Brosteanu O, de Waha S, Desch S, Gutberlet M, Schuler G, Thiele H.
    J Am Coll Cardiol; 2013 Apr 02; 61(13):1447-54. PubMed ID: 23466078
    [Abstract] [Full Text] [Related]

  • 8. Relationship between myocardial reperfusion, infarct size, and mortality: the INFUSE-AMI (Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction) trial.
    Brener SJ, Maehara A, Dizon JM, Fahy M, Witzenbichler B, Parise H, El-Omar M, Dambrink JH, Mehran R, Oldroyd K, Gibson CM, Stone GW.
    JACC Cardiovasc Interv; 2013 Jul 02; 6(7):718-24. PubMed ID: 23866184
    [Abstract] [Full Text] [Related]

  • 9. Intracoronary compared to intravenous bolus abciximab during primary percutaneous coronary intervention in ST-segment Elevation Myocardial Infarction (STEMI) patients reduces 30-day mortality and target vessel revascularization: a randomized trial.
    Iversen A, Abildgaard U, Galloe A, Hansen PR, Galatius S, Madsen JK, Engstroem T, Pedersen S, Jensen KS, Jensen JS.
    J Interv Cardiol; 2011 Apr 02; 24(2):105-11. PubMed ID: 21175845
    [Abstract] [Full Text] [Related]

  • 10. Intracoronary compared to intravenous abciximab in patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention reduces mortality, target vessel revascularization and reinfarction after 1 year.
    Iversen AZ, Galatius S, Abildgaard U, Galloe A, Hansen PR, Pedersen S, Engstroem T, Jensen JS.
    Cardiology; 2011 Apr 02; 120(1):43-9. PubMed ID: 22122887
    [Abstract] [Full Text] [Related]

  • 11. Intracoronary versus intravenous bolus abciximab administration in patients undergoing primary percutaneous coronary intervention with acute ST-elevation myocardial infarction: a pooled analysis of individual patient data from five randomised controlled trials.
    Piccolo R, Eitel I, Iversen AZ, Gu YL, Dominguez-Rodriguez A, de Smet BJ, Mahmoud KD, Abreu-Gonzalez P, Thiele H, Piscione F.
    EuroIntervention; 2014 Jan 22; 9(9):1110-20. PubMed ID: 24457282
    [Abstract] [Full Text] [Related]

  • 12. Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial.
    Thiele H, Wöhrle J, Hambrecht R, Rittger H, Birkemeyer R, Lauer B, Neuhaus P, Brosteanu O, Sick P, Wiemer M, Kerber S, Kleinertz K, Eitel I, Desch S, Schuler G.
    Lancet; 2012 Mar 10; 379(9819):923-931. PubMed ID: 22357109
    [Abstract] [Full Text] [Related]

  • 13. Intracoronary bolus-only compared with intravenous bolus plus infusion of tirofiban application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Kırma C, Erkol A, Pala S, Oduncu V, Dündar C, İzgi A, Tigen K, Gibson CM.
    Catheter Cardiovasc Interv; 2012 Jan 01; 79(1):59-67. PubMed ID: 21523892
    [Abstract] [Full Text] [Related]

  • 14. Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty.
    Wöhrle J, Grebe OC, Nusser T, Al-Khayer E, Schaible S, Kochs M, Hombach V, Höher M.
    Circulation; 2003 Apr 15; 107(14):1840-3. PubMed ID: 12682003
    [Abstract] [Full Text] [Related]

  • 15. Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty: a meta-analysis of 8 randomized trials.
    De Luca G, Verdoia M, Suryapranata H.
    Atherosclerosis; 2012 Jun 15; 222(2):426-33. PubMed ID: 22483166
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Meta-analysis of prospective randomized controlled trials comparing intracoronary versus intravenous abciximab in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Shimada YJ, Nakra NC, Fox JT, Kanei Y.
    Am J Cardiol; 2012 Mar 01; 109(5):624-8. PubMed ID: 22152971
    [Abstract] [Full Text] [Related]

  • 18. Effects of intracoronary compared to intravenous abciximab administration in patients undergoing transradial percutaneous coronary intervention: A sub-analysis of the EASY trial.
    Bertrand OF, Rodés-Cabau J, Larose E, Nguyen CM, Déry JP, Proulx G, Roy L, Poirier P, Costerousse O, De Larochellière R.
    Int J Cardiol; 2009 Aug 14; 136(2):165-70. PubMed ID: 18656274
    [Abstract] [Full Text] [Related]

  • 19. Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial.
    Zeymer U, Margenet A, Haude M, Bode C, Lablanche JM, Heuer H, Schröder R, Kropff S, Bourkaib R, Banik N, Zahn R, Teiger E.
    J Am Coll Cardiol; 2010 Aug 03; 56(6):463-9. PubMed ID: 20670755
    [Abstract] [Full Text] [Related]

  • 20. Infarct size and mortality in patients with proximal versus mid left anterior descending artery occlusion: the Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction (INFUSE-AMI) trial.
    Brener SJ, Witzenbichler B, Maehara A, Dizon J, Fahy M, El-Omar M, Dambrink JH, Genereux P, Mehran R, Oldroyd K, Parise H, Gibson CM, Stone GW.
    Am Heart J; 2013 Jul 03; 166(1):64-70. PubMed ID: 23816023
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 52.